Introduction {#Sec1}
============

Nowadays, dynamic intensity-modulated radiotherapy (d-IMRT) is widely used in the treatment of cancer patients. Compared with three dimensional conformal radiotherapy, d-IMRT allows to increase the dose conformity of the target while decreasing normal tissue doses \[[@CR1]\].

In dynamic IMRT plans, the multi-leaf collimators (MLCs) translate continuously at variable speeds during the irradiation while the upper and lower jaws stay static. According to the study by LoSasso et al. \[[@CR2]\], the MLC transmission increases with increasing jaw field size and beam energy. Cadman et al. \[[@CR3]\] found that the transmission through the jaw and the MLC together is smaller than 0.1%. Jaw tracking technique provided by linear accelerators keeps jaws during dose delivery as close as possible to the MLC aperture, and further minimizes leakage and transmission through the MLC leaves. Joy et al. \[[@CR4]\] evaluated the dosimetric effects of jaw tracking in step-and-shoot IMRT, but failed to indicate which patients would benefit most from jaw tracking. The dosimetric benefits of jaw tracking for prostate and head and neck (H&N) patients using d-IMRT and volumetric-modulated arc therapy (VMAT) were also evaluated by others \[[@CR5],[@CR6]\]. It showed that, the organs far from the target showed larger sparing in jaw-tracking static arc than the organs adjacent to the target. TrueBeam (Varian Medical Systems, Palo Alto, CA) is a new generation of linear accelerator providing jaw tracking technique (JTT), which traces the MLC aperture with jaws to minimize the leakage and transmission of the MLC leaves, hence further reduces the OAR doses adjacent to the target, and potentially improves the dose fall-off towards the surrounding critical structures.

The main purpose of this study is to assess the potential advantages of the JTT provided by TrueBeam accelerators in reducing the doses to the organs at risk (OARs) while preserving adequate target dose coverage, and to evaluate which patients and which OARs would benefit most from JTT plans.

Materials and methods {#Sec2}
=====================

Ethical consideration and consent {#Sec3}
---------------------------------

The use of the radiotherapy database for retrospective research has been approved by the committee of the Ethical Review Board of the Chinese Center for Disease Control and Prevention (No. LLSC2014-005). This research was waivered informed consent.

Patient characteristics {#Sec4}
-----------------------

Twenty eight cancer patients (median age 58 years, range 31--77 years) treated with radiotherapy in our department were retrospectively included in this study. The lesion distributions of the selected cases included head and neck, lungs, esophageal, abdominal, prostate, rectal and cervical, as shown in Table [1](#Tab1){ref-type="table"}. One local recurrent nasopharyngeal carcinoma (NPC) patient was included in the H&N group.Table 1**Lesion distributions and treatment characteristics of the selected casesLesion sitesnTotal dose (Gy)PTV (cm** ^**3**^ **)GTVCTVMean dose (range)Mean dose (range)MeanSD**Head and neck666.4(60--70)55.8(45--60)693.38168.8Lungs560.7(56--66)54.9(50.6-60)27050.07Esophageal465(64,66)50536.2839.4Abdominal353.5(50--60)46(45--48)454.1181.24Prostate27265(60,70)174.8535.75Rectal650.641.81163.5755.14Cervical2-47.5(45,50)1204.05139.45Abbreviations: *SD* standard deviation.

Contouring of targets and OARs {#Sec5}
------------------------------

All patients were immobilized with custom-made thermoplastic mask and underwent computed tomography (CT) scan with slice thickness of 3 mm (for head and neck patients) or 5 mm (for thoracic, abdominal and pelvic patients ) using the Siemens Somatom Sensation Open 40 slice CT scanner (Siemens, Forchheim, Germany). The targets and OARs were contoured slice by slice on the treatment planning CT images. Relevant organs were delineated for different anatomic regions. The body was segmented automatically by the Eclipse (Versions 11.0) Treatment Planning System (TPS) (Varian Medical Systems, Palo Alto, CA). Isotropic margins of 3 mm (for head and neck patients) or 5 mm (for thoracic, abdomen and pelvic patients) were created around the clinical target volume (CTV) and gross tumor volume (GTV) to generate the planning target volume (PTV) and planning gross tumor volume (PGTV), respectively.

Treatment planning {#Sec6}
------------------

The static jaw technique (SJT) d-IMRT plans were created using the Eclipse TPS using sliding window dynamic delivery and fixed beam angles. The selected energies were 6 MV (for head and neck patients) and 10 MV (for thoracic, abdominal and pelvic patients) respectively from a TrueBeam linear accelerator. The collimator angles were optimized according to the target shape. After IMRT optimization using the dose volume optimizer algorithm (version 11.0.31), the volumetric doses were calculated using the anisotropic analytical algorithm (version 11.0.31) with a dose calculation grid of 2 mm. The reference volume for the treatment planning was PTV. The normal tissue dose volume constraints used for the treatment planning are listed in Table [2](#Tab2){ref-type="table"}. For all patients, the dose distributions met the planning requirements, i.e. at least 95% of the PTV received the prescribed dose, while the doses to the surrounding tissues were minimized. To create JTT d-IMRT plans, the SJT d-IMRT plans were duplicated and jaw tracking function was selected when calculating the leaf motions and volumetric doses. All the machine parameters and optimization parameters were identical to those of the SJT d-IMRT plans. The JTT plans reduce the dose leakage and transmission through the MLCs, which required renormalization to achieve the same PTV coverage as in the SJT d-IMRT plans.Table 2**Dose constraints used in treatment planningOrganDose volume parametersOrganDose volume parameters**LensD~max~ \< 7GyHeartD~mean~ \< 26GyEyeD~max~ \< 50GyV~30~ \< 50%D~mean~ \< 35GyLiverD~mean~ \< 30GyOptic nerveD~max~ \< 54Gy1/3 volume of liver avoid irradiationBrain stemD~max~ \< 54GyKidneyD~mean~ \< 18GyParotidV~30~ \< 50%V~12~ \< 55%D~mean~ \< 26GyV~20~ \< 32%Spinal cordD~max~ \< 40GyIntestineV~40~ \< 30%EsophagusV~35~ \< 50%BladderV~30~ \< 50%D~mean~ \< 34GyFemoral HeadV~20~ \< 50%LungV~5~ \< 70%V~30~ \< 15%V~10~ \< 50%RectumV~30~ \< 50%V~20~ \< 30%V~60~ \< 35%D~mean~ \< 15GyV~70~ \< 20%

Plan evaluation {#Sec7}
---------------

The DVHs and the isodose curves of the JTT plans were compared with that of the SJT plans. The dose changes to the whole body were evaluated using V~5~, V~10~, V~20~, V~30~, V~40~, D~max~ and D~mean~ as listed in Table [3](#Tab3){ref-type="table"}. The parameters of V~5~, V~10~, V~20~, D~max~, and D~mean~ were used to evaluate the dose changes to the lungs, as shown in Table [4](#Tab4){ref-type="table"}. The dosimetric disparities of OARs were evaluated using the maximum dose (D~max~) and mean dose (D~mean~) as listed in Table [5](#Tab5){ref-type="table"} and Table [6](#Tab6){ref-type="table"}.Table 3**Comparison of the whole body doses between the two techniques (** $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \overline{\mathrm{X}}\pm \mathrm{s} $$\end{document}$ **)BodySJTJTTp**V~5~ (%)37.2 ± 19.136.1 ± 18.6\<0.001V~10~ (%)29.0 ± 16.528.2 ± 16.0\<0.001V~20~ (%)19.9 ± 12.919.3 ± 12.4\<0.001V~30~ (%)12.0 ± 9.611.6 ± 9.2\<0.001V~40~ (%)7.6 ± 7.07.5 ± 6.9\<0.001D~max~(Gy)60.3 ± 8.560.5 ± 8.80.071D~mean~(Gy)9.8 ± 6.09.6 ± 5.8\<0.001Table 4**Comparison of lung doses between the two techniques (** $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \overline{\mathrm{X}}\pm \mathrm{s} $$\end{document}$ **)LungSJTJTTp**V~5~ (%)48.3 ± 6.745.7 ± 5.9\<0.001V~10~ (%)34.9 ± 6.233.6 ± 5.8\<0.001V~20~ (%)20.5 ± 5.519.9 ± 5.1\<0.001D~max~(Gy)59.9 ± 6.460.00 ± 6.50.155D~mean~(Gy)11.4 ± 2.611.0 ± 2.5\<0.001Table 5**Comparison of OARs D** ~**max**~ **between the two techniques (** $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \overline{\mathrm{X}}\pm \mathrm{s} $$\end{document}$ **)OARs D** ~**max**~ **(Gy)SJTJTTp**Right lens5.6 ± 2.24.00 ± 1.70.031Left lens5.7 ± 1.64.2 ± 1.30.031Right eye26.3 ± 17.324.5 ± 17.80.031Left eye26.6 ± 13.924.9 ± 14.90.031Right optic nerve44.3 ± 8.943.4 ± 8.70.031Left optic nerve41.8 ± 10.840.8 ± 12.00.156Brain stem39.1 ± 12.037.2 ± 12.90.016Right parotid62.8 ± 10.963.2 ± 11.40.063Left parotid63.2 ± 7.363.6 ± 7.40.156Spinal cord31.0 ± 8.030.3 ± 7.9\<0.001Esophagus62.9 ± 5.562.8 ± 5.50.500Heart57.9 ± 5.957.9 ± 6.00.527Liver49.2 ± 6.149.2 ± 6.10.094Right kidney36.3 ± 15.936.3 ± 16.00.406Left kidney37.2 ± 9.337.0 ± 9.10.406Intestine50.6 ± 3.750.7 ± 3.90.313Bladder56.1 ± 9.056.2 ± 8.90.156Femoral head39.7 ± 5.239.8 ± 5.30.156Rectum60.6 ± 8.960.2 ± 9.40.156Table 6**Comparison of OARs D** ~**mean**~ **between the two techniques (** $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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                \begin{document}$$ \overline{\mathrm{X}}\pm \mathrm{s} $$\end{document}$ **)OARs D** ~**mean**~ **(Gy)SJTJTTp**Right lens4.9 ± 2.03.38 ± 1.440.031Left lens5.0 ± 1.43.59 ± 1.070.031Right eye7.1 ± 3.85.56 ± 3.550.031Left Eye7.7 ± 2.65.99 ± 2.830.031Right optic nerve25.5 ± 12.423.87 ± 13.330.031Left optic nerve26.0 ± 11.124.37 ± 12.260.031Brain stem23.7 ± 13. 522.03 ± 14.080.016Right parotid29.3 ± 4.927.41 ± 4.020.031Left parotid28.7 ± 4.127.23 ± 3.460.031Spinal cord19.0 ± 8.018.1 ± 7.6\<0.001Esophagus29.4 ± 8.428.9 ± 8.10.016Heart17.9 ± 11.917.5 ± 11.80.004Liver12.2 ± 9.911.9 ± 9.80.031Right kidney8.5 ± 4.18.2 ± 4.00.031Left kidney6.6 ± 4.86.3 ± 4.50.031Intestine27.4 ± 3.427.1 ± 3.40.016Bladder33.5 ± 8.733.1 ± 8.50.004Femoral head14.1 ± 1.613.7 ± 1.50.004Rectum35.8 ± 4.535.2 ± 4.70.031

Plan verification {#Sec8}
-----------------

The Eclipse TPS was used to create plans for verification by converting the SJT and JTT plans to OCTAVIUS Octagonal phantoms (PTW, Freiburg, Germany). Then the volumetric doses were re-calculated, and the dose distributions in effective measurement points of the two dimensional ionization chamber Array Seven29 (PTW, Freiburg, Germany) were exported for all plans. By using the γ evaluation method of VeriSoft software (version 5.1) (PTW, Freiburg, Germany), the measured dose planes were compared with the computed dose distribution using criteria of 3% dose difference and 3 mm distance to agreement.

Statistical analysis {#Sec9}
--------------------

The data were presented as the averages of all patients followed by the standard deviation ($\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
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                \begin{document}$$ \overline{\mathrm{X}}\pm \mathrm{s} $$\end{document}$). The PASW Statistics (version 18.0) software (SPSS; Chicago, IL, USA) was applied for statistical analysis. To compare the results of the two techniques, Wilcoxon Signed-Ranks test was performed with p values \<0.05 considered as significant.

Results {#Sec10}
=======

As shown in the DVH comparison (Figure [1](#Fig1){ref-type="fig"}), JTT d-IMRT plans reduce doses to the normal tissues, especially in the low dose regions.Figure 1**DVH comparison between SJT and JTT plans for different body sites: (a) H&N, (b) Thoracic, (c) Abdominal, (d) Pelvic case.** CTV: Clinical target volume; PTV: Planning target volume; GTV: Gross tumor volume; PGTV: Planning gross tumor volume.

Table [3](#Tab3){ref-type="table"} lists the comparison of the whole body doses between the two techniques. The JTT d-IMRT plans displayed significantly lower percentages of V~5~, V~10~, V~20~, V~30~, V~40~ and significantly lower mean doses of the whole body (p \< 0.001). There was no significant difference of maximum doses delivered to the whole body (p = 0.071).

Table [4](#Tab4){ref-type="table"} lists the statistical data of the lungs for all thoracic cases. The V~5~, V~10~, V~20~, D~mean~ of lungs in JTT d-IMRT plans are significantly lower than the corresponding values of the SJT d-IMRT plans (p \< 0.001), the mean reduction was 2.6%, 1.3%, 0.6% and 0.4%, respectively. There was no significant difference of maximum doses delivered to the lungs (p = 0.155).

This study demonstrates that the mean values of the maximum doses to the lens, eyes, brainstem, spinal cord, and right optic nerve are significantly reduced in the JTT plans (all p values \<0.05), as shown in Table [5](#Tab5){ref-type="table"}. The doses reduction for these OARs ranged from 2.2% to 28.6%, and the maximum dose to lens is reduced most obviously.

Table [6](#Tab6){ref-type="table"} lists the mean doses to various OARs for all patients. The JTT d-IMRT plans give significantly lower mean doses to the studied OARs (all p values \<0.05). The mean doses reduction for these OARs ranged from 1.1% to 31.0%, and the reduction values are depend on the volume and the location of the OARs.

Treatment plan verification of the two techniques is generally performed with the γ evaluation method. The γ was compared locally, and the γ pass rate for SJT and JTT is 93.9 ± 1.98 and 94.1 ± 1.95, respectively. The comparison of γ between the two techniques showed no statistical difference (p = 0.132). Dose calculation and delivery are both accurate for SJT and JTT plans at criteria of 3%/3 mm using γ analysis.

Discussion {#Sec11}
==========

Jaw tracking methods have also been used in other treatment modalities aiming to achieve better target coverage and critical structure sparing. Joy et al. \[[@CR4]\] evaluated the dosimetric effects of jaw tracking in step-and-shoot IMRT, showing an overall reduction of normal tissue doses. Most patients had reductions of V~5~, V~10~, and V~20~ by less than 2% in the normal tissues. Schmidhalter et al. \[[@CR5]\] evaluated the leaf transmission reduction using moving jaws in dynamic MLC IMRT, and demonstrated that the undesired doses to the body volume minus the planning target volume decreased by up to 1.8% and 1.5% for prostate and H&N patients. Simultaneously, the MU increased by up to 3.1% and 2.8%, respectively. Kim et al. \[[@CR6]\] assessed the potential advantages of jaw tracking technique by using control point sequences of VMAT planning, showing that, for H&N cases, the mean dose reductions for all the OARs ranged from 4.3% to 11.9%, and for prostate patients, the organs distant from the target were spared better in jaw-tracking static arc (JTSA) plans. The dose reductions were more significant in the dose regions of D~80~, D~90~ and D~95~ for all the patients in JTSA plans.

However, previous studies \[[@CR4]-[@CR6]\] included no abdominal cases or other pelvic lesion except prostate: the number of OARs was less than that of this study. Moreover, they didn't indicate which cases and which organs would benefit most from JTT.

This study selected cases of various body sites. For large and complex targets, such as NPC, the large target volumes are surrounded by many critical neural tissues and sensitive structures such as lens, optic nerves, brain stem, parotid glands and spinal cord. This study demonstrates that the mean values of the maximum doses to the lens, eyes, brainstem, spinal cord, and right optic nerve are significantly reduced in the JTT plans (all p values \<0.05) as shown in Table [5](#Tab5){ref-type="table"}. Perhaps because these OARs do not overlap with the target in the selected cases, yet the left optic nerve and other OARs are partially or wholly covered by PTVs. The reduction of the maximum dose to OARs may reduce the risk of radiation injury \[[@CR7],[@CR8]\], such as radiation induced myelitis and cataract. It is also more meaningful for the radiotherapy patients with local recurrent or second primary malignant lesion within or adjacent to a previously irradiated area.

The JTT technique also significantly reduces the low dose regions. In the thoracic cases, the JTT technique significantly reduces the V~5~, V~10~, V~20~ to the lungs, as shown in Table [4](#Tab4){ref-type="table"}, compared to the SJT plan (p \< 0.001). The results may mostly benefit Hodgkin's lymphoma patients whose lungs are largely within the treatment fields during radiotherapy. The JTT technique may reduce the risk of pulmonary toxicity since radiation pneumonitis rate is correlated with low dose volumes \[[@CR9]-[@CR12]\]. The risk of radiation induced secondary malignancies is another concern, which is strongly associated with low dose exposure of normal tissues during IMRT \[[@CR13]\].

In addition, this study suggests that the JTT plans give significantly lower mean doses to various OARs (all p values \<0.05, refer to Table [6](#Tab6){ref-type="table"} for details). The JTT associated OAR dose reductions are more obvious for the mean doses to the structures of small volume (such as lens) or structures far from the targets (such as left optic nerve, esophagus, and kidneys in this study). The mean doses of OARs have been widely used to predict the probability of radiation toxicity \[[@CR9]-[@CR12]\], such as pulmonary toxicity. Therefore, JTT plans may decrease the probability of developing late side effects or secondary neoplasm.

Some problems exist in the current jaw tracking technique though. Firstly, jaw tracking is not considered in the optimization of JTT d-IMRT or in the step-and-shoot jaw tracking IMRT plans \[[@CR4]\], as limited by the optimization algorithm of TPS. However, the Eclipse TPS (version 11.0) provides jaw tracking option in the VAMT plan optimization, which is applicable on Varian Truebeam accelerators. Secondly, the output factor of the accelerator varies dramatically in jaw tracking technique. Usually, the output factors are measured on the central axis of the beam. However, there are many off-axis fields in jaw tracking plans, which would affect the output factor and should be considered in treatment planning. Joy et al. \[[@CR4]\] calculated the off-axis output factors and demonstrated decreases of 1% to 3% when shifting away from central axis. Although all the SJT and JTT plans in this study can pass the dosimetric verification, this issue was not solved so far and further research is needed. Thirdly, the performance of flattening filter-free (FFF) module combined with the jaw tracking technique of TrueBeam accelerator is still uncertain. There were several reports \[[@CR14]-[@CR19]\] about the clinical usage of FFF beams, indicating more potential of reducing the doses to OARs with comparable target dose coverage. The potential benefit of applying jaw tracking technique in FFF beams will be further studied in the future work.

Conclusions {#Sec12}
===========

This study demonstrates that all the SJT and JTT plans could meet the clinical objectives and are clinically applicable. The dose measurements agreed well with TPS calculated doses. JTT displays superior OARs sparing than SJT plans. These results are of clinical importance, especially for the patients with large and complex targets but close to some highly radio-sensitive organs to spare (such as lens or gonad), and for patients with local recurrent or secondary primary malignant lesion within a previously irradiated area. More studies on off-axis output factors and combined application of FFF module should be conducted in the future.
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